Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA).
| Abstract Titles and Presenters | Presentation Details | |
| NXP800 | NXP800, a novel, small molecule GCN2 kinase activator,demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft modelsPresenter: Ramez N. EskanderDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences University of California San Diego La Jolla, CA, USA | Session Title Poster Session ASession Type PosterSession Date / Time November 16th, 7:30-9:00 PM |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating its potential to treat platinum resistant, ARID1a-mutated ovarian carcinoma. The FDA granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule SRC/YES1 kinase family (SFK) inhibitor currently in a Phase 1a dose escalation clinical trial.
Company Contact
Ron Bentsur Chairman, Chief Executive Officer and President 201-614-3151 rbentsur@nuvectis.com
Media Relations Contact
Christopher M. Calabrese LifeSci Advisors Tel: 917-680-5608 ccalabrese@lifesciadvisors.com
